Karen Krasney Sells Shares of Capricor Therapeutics

Karen Krasney, Executive Vice President and General Counsel at Capricor Therapeutics, Inc. (NasdaqGS:CAPR), sold 400 shares of the company on June 24, 2026. The shares were sold at an average price of $30 each, amounting to a total transaction value of $12,000. This transaction was not conducted under a pre-planned 10b5-1 trading plan.

Insider Buying and Selling at Capricor Therapeutics, Inc.

In addition to Karen Krasney's recent sale, there were other transactions on the same day. Anthony Bergmann, the Chief Financial Officer, also sold 400 shares at $30 each. Interestingly, both Krasney and Bergmann also made purchases of 400 shares each at a lower price of $3.18 earlier in the day, indicating possible strategic trading activity.

Other Institutional Activity in Capricor Therapeutics

Several institutional investors have been active in Capricor Therapeutics. Suvretta Capital Management, LLC increased its holdings by 2,032,990 shares, reaching a total of 3,818,600 shares valued at approximately $116.1 million, marking a 113.9% increase. BlackRock, Inc. added 570,837 shares, bringing its total to 3,421,815 shares worth about $104 million, a 20% rise. Tang Capital Management LLC doubled its position by adding 1,699,900 shares, totaling 3,399,900 shares valued at $103.4 million. State Street Corp grew its stake by 1,352,380 shares, reaching 2,181,901 shares valued at $66.3 million, a 163% increase. Vanguard Capital Management LLC opened a new position with 2,027,732 shares valued at $61.6 million.

Capricor Therapeutics, Inc. Stock Up 207.7%

Shares of Capricor Therapeutics traded near $29.60 on Thursday. The company has a market capitalization of about $1.7 billion. It operates in the biotechnology sector and has a forward P/E ratio of -38.42, indicating it is not yet profitable. The stock's 52-week range is between $4.30 and $40.37, with a 50-day moving average of $30.58 and a 200-day moving average of $21.38. Capricor has a current ratio of 8.42 and a quick ratio of 8.28, suggesting strong liquidity.

Analysts Set New Price Targets

Analysts remain optimistic about Capricor Therapeutics. On March 13, 2026, B. Riley Securities maintained a buy rating with a $63 price target. Piper Sandler reiterated a buy rating on the same day with a $58 target. HC Wainwright & Co. also reiterated a buy rating with a $60 target on March 10, 2026. The consensus among analysts is a strong buy, with a mean price target of $54.11.

About Capricor Therapeutics

Capricor Therapeutics, Inc. is a biotechnology company based in San Diego, California. Founded in 2005, it focuses on developing cell and exosome-based therapeutics for various diseases, including Duchenne muscular dystrophy (DMD). Its lead product, Deramiocel, is in phase 3 trials for DMD, while its exosome platform is being developed for vaccine and therapeutic applications. Dr. Linda Marbán, Ph.D., serves as the company's CEO, overseeing a team of 231 employees.

Bottom Line

Karen Krasney's recent sale of Capricor Therapeutics shares is part of a broader pattern of insider transactions at the company. Investors often track such moves for potential insights into company sentiment. The company remains a focus for analysts, who continue to rate it as a strong buy. As always, it is important to remember that insider trades and 13F filings reflect past actions and may not indicate future moves.